| pubmed-article:11354383 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11354383 | lifeskim:mentions | umls-concept:C0002482 | lld:lifeskim |
| pubmed-article:11354383 | lifeskim:mentions | umls-concept:C1708096 | lld:lifeskim |
| pubmed-article:11354383 | lifeskim:mentions | umls-concept:C0449829 | lld:lifeskim |
| pubmed-article:11354383 | lifeskim:mentions | umls-concept:C1152633 | lld:lifeskim |
| pubmed-article:11354383 | lifeskim:mentions | umls-concept:C0205088 | lld:lifeskim |
| pubmed-article:11354383 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11354383 | pubmed:dateCreated | 2001-5-16 | lld:pubmed |
| pubmed-article:11354383 | pubmed:abstractText | Several 1,4-disubstituted arylpiperazine derivatives of 3-arylideneindolin-2(1H)-one (Z and E isomers) were tested for their 5-HT1A and 5-HT2A receptor activity in vitro and in vivo. It was shown that introduction of 3-arylidene substituents to indolin-2(1H)-one moiety allowed to change the mixed 5-HT1A/5-HT2A receptor ligands to 5-HT2A ones with antagonistic in vivo activity. | lld:pubmed |
| pubmed-article:11354383 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11354383 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11354383 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11354383 | pubmed:month | May | lld:pubmed |
| pubmed-article:11354383 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:11354383 | pubmed:author | pubmed-author:Chojnacka-Wój... | lld:pubmed |
| pubmed-article:11354383 | pubmed:author | pubmed-author:Charakchieva-... | lld:pubmed |
| pubmed-article:11354383 | pubmed:author | pubmed-author:K?odzi?skaAA | lld:pubmed |
| pubmed-article:11354383 | pubmed:author | pubmed-author:MokroszM JMJ | lld:pubmed |
| pubmed-article:11354383 | pubmed:author | pubmed-author:Kozio?AA | lld:pubmed |
| pubmed-article:11354383 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11354383 | pubmed:day | 7 | lld:pubmed |
| pubmed-article:11354383 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:11354383 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11354383 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11354383 | pubmed:pagination | 1229-31 | lld:pubmed |
| pubmed-article:11354383 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:meshHeading | pubmed-meshheading:11354383... | lld:pubmed |
| pubmed-article:11354383 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11354383 | pubmed:articleTitle | Influence of the terminal amide fragment geometry in some 3-arylideneindolin-2(1H)-ones on their 5-HT1A/5-HT2A receptor activity. | lld:pubmed |
| pubmed-article:11354383 | pubmed:affiliation | Department of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Kraków. | lld:pubmed |
| pubmed-article:11354383 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:11354383 | lld:chembl |
